#USA #New York #Securities Fraud #Pomerantz #EyePoint

Investigation of EyePoint, Inc. by Pomerantz Law Firm

Pomerantz LLP, a well-respected firm specializing in corporate law, has announced it is investigating potential claims related to EyePoint, Inc. (NASDAQ: EYPT). This investigation is particularly focused on the company’s recent struggles with its clinical trial results and the following implications for investors.

Background on EyePoint, Inc.

Founded with a vision to transform the treatment landscape for eye diseases, EyePoint, Inc. has made strides in developing therapies for conditions such as wet age-related macular degeneration (wet AMD). Their flagship product, DURAVYU™ (vorolanib intravitreal insert), was recently at the center of scrutiny following the publication of the results from their pivotal Phase 3 clinical trials.

Recent Developments and Clinical Trials

On August 17, 2026, EyePoint shared results from its LUGANO trial, claiming to assess the efficacy of DURAVYU against Regeneron’s Eylea. Unfortunately, the results were disappointing, as they did not demonstrate an improvement in best corrected visual acuity, which is crucial for assessing the effectiveness of eye treatments. This news lead to a staggering 66.98% drop in EyePoint’s stock price, causing it to plummet to $4.87 per share.

The situation worsened for EyePoint investors when, on October 19, 2026, the company announced further setbacks from its follow-up LUCIA trial. This trial's results indicated that DURAVYU failed to meet primary efficacy endpoints, prompting drastic actions from EyePoint, including significant layoffs and the immediate cessation of its wet AMD clinical program. The stock price then spiraled downward even further, falling to just $0.44 per share, marking an 85.28% decrease from its pre-announcement value.

Investigation by Pomerantz LLP

In light of these developments, Pomerantz LLP aims to determine whether EyePoint and specific corporate officers may have engaged in securities fraud or related unlawful practices concerning the recent clinical trial disclosures. Investors who feel they may have been misled about the viability of EyePoint’s products are encouraged to reach out to the firm. Danielle Peyton from Pomerantz is the main contact for any inquiries regarding the investigation.

Given the seriousness of these allegations, Pomerantz LLP is leveraging its extensive experience in corporate litigation, having successfully facilitated numerous class-action lawsuits in the past, to seek justice for affected investors.

What This Means for EyePoint Investors

The situation signifies a crucial moment for EyePoint investors, as the investigation may reveal deeper insights into the company’s strategies leading up to the clinical trial announcements, and whether adequate precautions were taken to inform shareholders. The outcome could pave the way for potential legal action against the company if misconduct is established.

Investors are advised to stay vigilant and possibly participate in the class-action investigation to safeguard their rights and financial interests. As this situation develops, it serves as a reminder of the volatile nature of biomedical investments, highlighting the need for thorough due diligence in order to navigate potential pitfalls effectively.

For those who invested in EyePoint, this ongoing investigation will be key in assessing future actions.

For more detailed information or to join the efforts led by Pomerantz LLP, prospective parties can connect with the firm directly via provided contact details.